vvz-149
Small moleculeexperimental
Clinical trial activity
13 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
9
Phase 3
3
Phase 4
0
Earliest trial started Jul 1, 2013 (NCT01905410)
Timeline
Indications
Mechanism of action
- Glycine transporter 2ANTAGONIST
SLC6A5 antagonist
- Serotonin 2a (5-HT2a) receptorANTAGONIST
HTR2A antagonist
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- vvz-149
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05764525 | Phase 3 | Jul 19, 2021 | Vivozon, Inc. |
| NCT04430088 | Phase 3 | Jun 30, 2020 | Vivozon, Inc. |
| NCT04415645 | Phase 1 | Feb 24, 2020 | Vivozon, Inc. |
| NCT03997838 | Phase 3 | May 23, 2019 | Vivozon, Inc. |
| NCT03997812 | Phase 2 | May 23, 2019 | Vivozon, Inc. |
| NCT03347266 | Phase 2 | Nov 30, 2017 | Vivozon, Inc., Yonsei University |
| NCT02992041 | Phase 2 | Dec 1, 2016 | Vivozon, Inc. |
| NCT02844725 | Phase 2 | May 1, 2016 | Vivozon, Inc., Yonsei University |
| NCT02644421 | Phase 1 | Nov 1, 2015 | Harvard University |
| NCT02522598 | Phase 2 | Aug 1, 2015 | Vivozon, Inc., Yonsei University |
| NCT02489526 | Phase 2 | Aug 1, 2015 | Vivozon, Inc. |
| NCT02333318 | Phase 1 | Jul 1, 2014 | Seoul National University, Vivozon, Inc. |
| NCT01905410 | Phase 1 | Jul 1, 2013 | Seoul National University, Vivozon, Inc. |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Vivozon, Inc. | For profit | 12 | 12 | 3 | 2013 |
| Yonsei University | Academic/Hospital | 3 | 0 | 1 | 2015 |
| Seoul National University | Academic/Hospital | 2 | 0 | 1 | 2013 |
| Harvard University | Academic/Hospital | 1 | 1 | 1 | 2015 |
4 organizations
Page 1 / 1